Pyridine-containing octadentate ligand NE3TA-PY for formation of neutral complex with 177 Lu(III) and 90 Y(III) for radiopharmaceutical applications: Synthesis, DFT calculation, radiolabeling, and in vitro complex stability

Targeted radionuclide therapy is a developing therapeutic modality for cancer and employs a cytotoxic radionuclide bound to a chelating agent and a bioactive molecule with high binding affinity for a specific biomarker in tumors. An optimal chelator is one of the critical components to control thera...

Ausführliche Beschreibung